CHPA: Sunscreen Efficacy Ceiling Is More Harmful Than SPF Claim Limit
This article was originally published in The Tan Sheet
FDA should not impose an efficacy ceiling on sunscreen formulations even if it caps sun protection factor label claims at 50 or 50+, industry stakeholders argue.
You may also be interested in...
Procter & Gamble files comments in support of FDA’s proposed 50+ SPF cap for OTC sunscreens, maintaining that high-SPF products do not provide a significant incremental protective benefit. P&G also cites harmonization with international regulatory frameworks in comments to FDA.
As early as June 2012, sunscreens that fail “broad spectrum” tests or have an SPF less than 15 must warn that they have not been shown to prevent cancer or early skin aging, according to an FDA final rule.
FDA might cap sun protection values at 50 or 50+ so as not to mislead consumers about the clinical benefit of sunscreens with higher SPF values, according to a proposed rule.